Literature DB >> 1557125

Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation.

E Gussoni1, G K Pavlath, A M Lanctot, K R Sharma, R G Miller, L Steinman, H M Blau.   

Abstract

Gene delivery by transplantation of normal myoblasts has been proposed as a treatment of the primary defect, lack of the muscle protein dystrophin, that causes Duchenne muscular dystrophy (DMD), a lethal human muscle degenerative disorder. To test this possibility, we transplanted normal myoblasts from a father or an unaffected sibling into the muscle of eight boys with DMD, and assessed their production of dystrophin. Three patients with deletions in the dystrophin gene expressed normal dystrophin transcripts in muscle biopsy specimens taken from the transplant site one month after myoblast injection. Using the polymerase chain reaction we established that the dystrophin in these biopsies derived from donor myoblast DNA. These results show that transplanted myoblasts persist and produce dystrophin in muscle fibres of DMD patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1557125     DOI: 10.1038/356435a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  88 in total

Review 1.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

2.  Progressive atrioventricular conduction block in a mouse myotonic dystrophy model.

Authors:  C I Berul; C T Maguire; J Gehrmann; S Reddy
Journal:  J Interv Card Electrophysiol       Date:  2000-06       Impact factor: 1.900

3.  Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration.

Authors:  Ingo Riederer; Elisa Negroni; Maximilien Bencze; Annie Wolff; Ahmed Aamiri; James P Di Santo; Suse D Silva-Barbosa; Gillian Butler-Browne; Wilson Savino; Vincent Mouly
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

4.  Sparing of extraocular muscle in aging and muscular dystrophies: a myogenic precursor cell hypothesis.

Authors:  Kristen M Kallestad; Sadie L Hebert; Abby A McDonald; Mark L Daniel; Sharon R Cu; Linda K McLoon
Journal:  Exp Cell Res       Date:  2011-01-27       Impact factor: 3.905

5.  Monoclonal antibodies for dystrophin analysis. Epitope mapping and improved binding to SDS-treated muscle sections.

Authors:  T M Nguyen; I B Ginjaar; G J van Ommen; G E Morris
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

6.  Transferring myoblasts in Duchenne dystrophy.

Authors:  V Dubowitz
Journal:  BMJ       Date:  1992-10-10

Review 7.  Recent advances in understanding muscular dystrophy.

Authors:  K M Bushby
Journal:  Arch Dis Child       Date:  1992-10       Impact factor: 3.791

8.  Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.

Authors:  Noah Weisleder; Norio Takizawa; Peihui Lin; Xianhua Wang; Chunmei Cao; Yan Zhang; Tao Tan; Christopher Ferrante; Hua Zhu; Pin-Jung Chen; Rosalie Yan; Matthew Sterling; Xiaoli Zhao; Moonsun Hwang; Miyuki Takeshima; Chuanxi Cai; Heping Cheng; Hiroshi Takeshima; Rui-Ping Xiao; Jianjie Ma
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

Review 9.  Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish.

Authors:  Louis M Kunkel; Estanislao Bachrach; Richard R Bennett; Jeffrey Guyon; Leta Steffen
Journal:  J Hum Genet       Date:  2006-04-01       Impact factor: 3.172

Review 10.  Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications.

Authors:  Joseph G Moloughney; Noah Weisleder
Journal:  Recent Pat Biotechnol       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.